Sai Life Sciences shares are up nearly 9% after the company reports a 17% year-on-year increase in second-quarter net profit and a 23% rise in revenue. The move lifts the stock to a fresh 52-week high, reflecting investor focus on the firm’s operating momentum and results for the quarter.

Across outlets, the reporting centers on the same core performance metrics: revenue growth to ₹659 crore and net profit increase to ₹98 crore for the quarter ended September 2026. Economic Times emphasizes the market reaction and the overall improvement in profitability, while Free Press Journal provides more granular detail from the company’s regulatory filing, including EBITDA growth and margin changes. Free Press Journal also adds context on capital expenditure, saying the company spent ₹621 crore in the first half of FY27 to expand manufacturing capacity and strengthen operational capabilities, alongside commentary about evolving customer relationships.

For the first half of FY27, Free Press Journal reports revenue growth and higher profit after tax, reinforcing a continuing trend beyond the quarter. Overall, the differences are mainly in emphasis—market reaction and momentum versus additional financial breakdown and expansion investment.